期刊文献+

Preliminary Study on a Potential Panel for Quality Assurance of ELISPOT

Preliminary Study on a Potential Panel for Quality Assurance of ELISPOT
下载PDF
导出
摘要 The ELISPOT assay is increasingly used for assessing cellular immune responses in clinical trials of HIV-1 or cancer vaccines. However, to date, data from clinical trials do not consistently show that immune responses are correlated with clinical endpoints. This is due in part to the lack of assay standardization and validation across laboratories and therefore, a quality control panel is required to establish competency and comparability amongst different laboratories. In this study peripheral blood mononuclear cells (PBMCs) from healthy individuals were screened and frozen in liquid nitrogen. The recovery and viability of the PBMCs and the frequencies of interferon (IFN)-γ-secreting cells after CEF peptide pool stimulation were detected after various intervals in seven different laboratories. The recovery and viability did not differ significantly after different intervals. Although the frequencies of IFN (interferon)-γ-secreting cells among thawed PBMCs (peripheral blood mononuclear cells) fluctuated after CEF peptide pool stimulation at different intervals, they were not significantly decreased compared with those among fresh PBMCs. However, the viabilities, recoveries and frequencies of IFN-γ-secreting cells differed significantly among the seven laboratories. Our results indicate that cryopreserved PBMCs could be used as a quality control panel for ELISPOT. However, the procedures for ELISPOT need to be standardized amongst different laboratories. The ELISPOT assay is increasingly used for assessing cellular immune responses in clinical trials of HIV-1 or cancer vaccines. However, to date, data from clinical trials do not consistently show that immune responses are correlated with clinical endpoints. This is due in part to the lack of assay standardization and validation across laboratories and therefore, a quality control panel is required to establish competency and comparability amongst different laboratories. In this study peripheral blood mononuclear cells (PBMCs) from healthy individuals were screened and frozen in liquid nitrogen. The recovery and viability of the PBMCs and the frequencies of interferon (IFN)-γ-secreting cells after CEF peptide pool stimulation were detected after various intervals in seven different laboratories. The recovery and viability did not differ significantly after different intervals. Although the frequencies of IFN (interferon)-γ-secreting cells among thawed PBMCs (peripheral blood mononuclear cells) fluctuated after CEF peptide pool stimulation at different intervals, they were not significantly decreased compared with those among fresh PBMCs. However, the viabilities, recoveries and frequencies of IFN-γ-secreting cells differed significantly among the seven laboratories. Our results indicate that cryopreserved PBMCs could be used as a quality control panel for ELISPOT. However, the procedures for ELISPOT need to be standardized amongst different laboratories
出处 《Virologica Sinica》 SCIE CAS CSCD 2008年第5期330-338,共9页 中国病毒学(英文版)
关键词 ELISPOT Peripheral blood mononuclear cells (PBMCs) CRYOPRESERVATION INTERFERON-Γ CEFpeptide pools 斑点法 细胞 免疫系统 测试方法
  • 相关文献

参考文献11

  • 1[1]Arlen P,Tsang K Y,Marshall J L,et al.2000.The use of a rapid ELISPOT assay to analyze peptide-specific immune response in carcinoma patients to peptide versus recombinant poxvirus vaccines.Cancer Immunol Immunother,49:517-529.
  • 2[2]Asai T,Storkus W J,Whiteside T L,2000.Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines.Clin Diagn Lab Immunol,7:145-154.
  • 3[3]Cox J H,Ferrari G,Kalams S A,et al.2005.Results of an ELISPOT Proficiency Panel Conducted in 11 Laboratories Participating in International Human Immunodeficiency Virus Type 1 Vaccine Trials.AIDS Research and Human Retroviruses,21:68-81.
  • 4[4]Currier J R,Kuta E G,Turk E,et al.2002.A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays.J Immunol Methods,260:157-172.
  • 5[5]Doherty T M,Demissie A,Menzies D,et al.2005.Effect of sample handling on analysis of cytokine responses to Mycobacterium tuberculosis in clinical samples using ELISA,ELISPOT,and quantitative PCR.J Immunol Methods,298:129-141.
  • 6[6]Kvarnstrom M,Jenmalm M C,EkerfeR C.2004.Effect of cryopreservation on expression of Thl and Th2 cytokines in blood mononuclear cells from patients with different cytokine profiles,analysed with three common assays:an overall decrease of interleukin-4.Cryobiology,49:157-168
  • 7[7]Maecker H T,Moon J,Bhatia S,et al.2005.Impact of cryopreservation on tetramer,cytokine flow cytometry,and ELISPOT.BMC Immunol,6:17.
  • 8[8]McCutcheon M,Wehner N,Wensky A,et al..1997.A sensitive ELISPOT assay to detect low-frequency human T lymphocytes.J Immunol Methods,210:149-166.
  • 9[9]Mwan M,McMichael A J,Hanke T.2002.Design and validation of an enzyme-linked immunospot assay for use in clinical trials of candidate HIV vaccines.AIDS Res Hum Retrovirnses,18:611-618
  • 10[10]Power C A,Grand C L,Ismail N,et al.1999.A valid ELISPOT assay for enumeration of ex vivo,antigenspecifie,IFN-γ,producing cells.J Immunol Methods,227:99-107

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部